

Resource Summary Report

Generated by [kravitz2](#) on Aug 12, 2026

Beckman Coulter: CytoFLEX LX Flow Cytometer

RRID:SCR_025067

Type: Tool

Proper Citation

Beckman Coulter: CytoFLEX LX Flow Cytometer (RRID:SCR_025067)

Resource Information

URL: <https://www.beckman.com/flow-cytometry/research-flow-cytometers/cytoflex-lx>

Proper Citation: Beckman Coulter: CytoFLEX LX Flow Cytometer (RRID:SCR_025067)

Description: This model is equipped with four lasers (405, 488 561 and 638nm), and is capable of detecting FSC, SSC and 16 colors.

Synonyms: Beckman Coulter CytoFLEX LX, CytoFLEX LX

Resource Type: instrument resource

Resource Name: Beckman Coulter: CytoFLEX LX Flow Cytometer

Resource ID: SCR_025067

Alternate IDs: Model_Number_CytoFLEX LX

Alternate URLs: <https://biotech.unl.edu/flow-cytometry#tab5>

Record Creation Time: 20240305T200904+0000

Record Last Update: 20260808T190718+0000

Ratings and Alerts

No rating or validation information has been found for Beckman Coulter: CytoFLEX LX Flow Cytometer.

No alerts have been found for Beckman Coulter: CytoFLEX LX Flow Cytometer.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Fang C, et al. (2026) Base Editing of TIGIT Reprograms CD155 Signaling in Natural Killer Cells to Enhance Cancer Immunotherapy Efficacy. *Cancer research*, 86(8), 1956.

Esapa B, et al. (2026) An antibody-drug conjugate designed through clone and isotype selection restricts the growth of CSPG4-expressing triple-negative breast cancer. *NPJ precision oncology*, 10(1).

Bai G, et al. (2026) LARS promotes osteosarcoma proliferation through leucine-dependent PRIM2 translation and DNA replication activation. *Journal of experimental & clinical cancer research : CR*, 45(1).

Shah UA, et al. (2026) A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model. *Cancer discovery*, 16(4), 697.

Brevi A, et al. (2026) Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression. *Cancer research*, 86(12), 2860.

Kohl S, et al. (2026) CXCR2 affects sensitization of radioresistant HPV-negative head and neck squamous cell carcinoma cells by ABT-263. *Radiation oncology (London, England)*, 21(1), 33.

Vuong TT, et al. (2026) DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment. *Cancer research communications*, 6(7), 1721.

Benjamin JS, et al. (2025) 23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation. *Cancer research communications*, 5(3), 476.

Zhou Y, et al. (2025) Myosin-actin pattern links matrix stiffness to GFAT2-hyaluronan metabolism. *Materials today. Bio*, 35, 102305.

Campo F, et al. (2025) Bioengineering of a human iPSC-derived vascularized endocrine pancreas for type 1 diabetes. *Cell reports. Medicine*, 6(2), 101938.

Chenoweth AM, et al. (2025) An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer. *Cancer research*, 85(22), 4521.

Rajput S, et al. (2025) SBFI Inhibitors Reprogram Transcriptomic Landscape of Prostate Cancer Cells Leading to Cell Death. *Cancers*, 17(23).

Giuntini F, et al. (2025) MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer. *Cell reports*, 44(12), 116604.

Cao C, et al. (2024) CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8⁺ T cells via JAK2/STAT3 pathway. *Cell genomics*, 4(10), 100659.

Shouse AN, et al. (2024) Interleukin-2 receptor signaling acts as a checkpoint that influences the distribution of regulatory T cell subsets. *iScience*, 27(12), 111248.